UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 11, 2023

INNOVATION1 BIOTECH INC.

(Exact name of registrant as specified in its charter)

Nevada	000-55852	82-2275255
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

179 Route 46W, Suite 15 #147 Rockaway, New Jersey		07866
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (929) 459-4966

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On October 11, 2023, Innovation1 Biotech Inc. (the “Company”) issued a $20,000 Demand Promissory Note (the “Note”) to an accredited investor in consideration for $20,000. The Note: (i) bears 10% interest per annum and (ii) matures on the earlier of January 9, 2024, and five days from the date that the noteholder demands repayment.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Exhibit Description

4.1		Form of Demand Promissory Note
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Innovation1 Biotech Inc.

Date: October 16, 2023	By:	/s/ Frederick E. Pierce
	Name:	Frederick E. Pierce
	Title:	Interim Acting Chief Executive Officer
		Principal Executive and Principal Accounting Officer

Innovation1 Biotech Inc. 8-K